SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing significant trading volume and renewed community speculation as traders rotate into Japanese blockchain projects and IoT-focused assets. While investors remain divided by the token's historical price volatility, the conversation is dominated by technical breakout potential and anticipation of long-term ecosystem development despite broader market uncertainty.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad ($GIGA) is experiencing a wave of community optimism driven by its recent expansion into real-world fitness supplements and a durable, long-standing cult-like following on Solana. Investors are actively debating its potential for a massive repricing, frequently comparing its long-term growth trajectory to established market leaders while highlighting its low market cap as a high-risk, high-reward asymmetric opportunity.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending due to intense community debate over its business model, with many investors viewing the stock as a real estate and royalty machine rather than just a fast-food chain. While supporters highlight its long-term compounding and dividend reliability, significant volatility is being driven by customer and investor backlash regarding value menu pricing and recent management commentary.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

Investors are flocking to this leveraged ETF as a high-volatility vehicle to capture momentum in the semiconductor and memory chip sector, driven by bullish narratives surrounding supply shortages and production demand. The community is actively debating the risks and rewards of maintaining leveraged exposure during rapid price swings, with many traders sharing strategies on how to navigate the volatility through short-term positioning.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is currently a focal point for investors as the broader Bitcoin market navigates heightened volatility, driven by speculation over geopolitical tensions in the Middle East and shifting institutional sentiment regarding crypto's role as a digital reserve asset. Community discussions are heavily centered on Bitcoin's price action at key support levels and the potential impact of ETF flows on market liquidity amid conflicting macroeconomic signals.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding late-breaking clinical data for the CHOPIN trial, which is expected to showcase the efficacy of its HEPZATO KIT in combination therapies. The community is actively discussing the companys expansion into additional indications like metastatic colorectal and breast cancer, while debating the significance of recent hospital network growth versus the stock's stagnant price action and short-term revenue fluctuations.

Amphenol Corp. engages in the design, manufacture, and marketing of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products, and specialty cable. It operates through the following segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The Harsh Environment Solutions segment manufactures and markets a broad range of ruggedized interconnect products, including connectors and interconnect systems, printed circuits and printed circuit assemblies, and other products. The Communications Solutions segment focuses on the design, manufacture, and marketing of connector and interconnect systems, including radio frequency, power, fiber optic, and other products, together with antennas. The Interconnect and Sensor Systems segment is involved in the design, manufacture, and marketing of sensors, sensor-based systems, connectors, and value-add interconnect systems. The company was founded by Schmitt J. Arthur in 1932 and is headquartered in Wallingford, CT.

Amphenol Corp. - Ordinary Shares - Class A

Amphenol is drawing significant investor interest as it continues to capitalize on strong demand for data center infrastructure and AI-related interconnect technology, despite some community concerns regarding executive stock sales and high valuation multiples. Market sentiment is split, with bulls pointing to the company's robust backlog and order growth as proof of its long-term compounding potential, while bears remain focused on its premium price-to-earnings ratio and broader sector volatility.

Ethereum Classic

Ethereum Classic is currently trending as investors debate the potential for an altcoin rally, with the community closely tracking its strength relative to Bitcoin and other major assets. Discussions are polarized, balancing optimism around its proof-of-work model and long-term utility against frustrations over its extended period of price stagnation.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending as the community debates its transition from a speculative R&D-stage company to a commercial player, with investors closely watching for foundry partnerships and scalable manufacturing validation. Market discussion is heavily focused on the company's potential role in the AI and photonics infrastructure space, juxtaposed against concerns over stock dilution from at-the-market offerings and high short interest.

Roundhill ETF Trust - Roundhill Memory ETF

The $DRAM ETF is trending as investors rotate into memory and storage leaders like SK Hynix, Samsung, and Micron to capitalize on a persistent AI-driven supply bottleneck. The community is actively discussing the ETF's concentrated structure as a direct, non-leveraged beta proxy for the memory super-cycle, while debating strategies for manual replication versus holding the fund directly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +40.00% and +164.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Plus has appointed Eric J. Daniels as its chief development officer, effective April 20.</li><li>The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.</li></ul>Shares of Plus Therapeutics Inc. (PSTV) rallied 24% on Friday on the heels of the company announcing the appointment of a new chief development officer (CDO) and the U.S. Food and Drug Administration granting its experimental therapy an orphan drug designation.The stock is on track to record its best week since late September if the gains hold.Plus Therapeutics announced a 1-for-25 stock split last month in a bid to meet Nasdaq’s requirements for minimum share price for continued trading on the bourse. The stock began trading on a post-split basis on April 2.Houston, Texas-headquartered Plus has since announced that it has appointed Eric J. Daniels as its CDO, effective April 20. Daniels most recently was CDO at Kiora Pharmaceuticals, overseeing the company’s clinical, preclinical, and Chemistry, Manufacturing, and Controls (CMC) activities, Plus said.The company also said earlier this week that the FDA has granted Orphan Drug Designation to its radiotherapeutic REYOBIQ for the treatment of pediatric malignant gliomas, or aggressive brain tumors.Orphan Drug Designation is granted by the FDA to investigational therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides several potential benefits including tax credits, fee waivers, and potential market exclusivity.The company also said that it received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PSTV stock stayed within the ‘extremely bullish’ territory over the past 12 months, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed pessimism about the company’s new CDO appointment, noting that Kiora shares slumped over the past year.<stembedurl>https://www.stocktwits.com/andre82/message/649952051</stembedurl>Yet another, however, said that the stock is very undervalued.<stembedurl>https://www.stocktwits.com/RadioIsotope25/message/649951802</stembedurl><a href="https://stocktwits.com/symbol/PSTV">PSTV stock</a> has dropped about 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 

Equity

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 


Why Is Plus Therapeutics Stock Gaining Friday?

Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain cancer, boosting long-term outlook.read more...

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's Why

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's What Happened...

Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4

Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +35.47% and +128.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardian Pharmacy Services (GRDN) Surpasses Q4 Earnings and Revenue Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +37.04% and +2.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company...

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Plus Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTV News

PSTVPlus Therapeutics Inc